- Home
- PHX vs CNTX Comparison
PHX vs CNTX Comparison
Compare PHX & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHX
- CNTX
- Stock Information
- Founded
- PHX 1926
- CNTX 2015
- Country
- PHX United States
- CNTX United States
- Employees
- PHX N/A
- CNTX N/A
- Industry
- PHX Oil & Gas Production
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- PHX Energy
- CNTX Health Care
- Exchange
- PHX Nasdaq
- CNTX Nasdaq
- Market Cap
- PHX 137.2M
- CNTX 149.6M
- IPO Year
- PHX N/A
- CNTX 2021
- Fundamental
- Price
- PHX $3.45
- CNTX $1.95
- Analyst Decision
- PHX Strong Buy
- CNTX Strong Buy
- Analyst Count
- PHX 2
- CNTX 3
- Target Price
- PHX $4.90
- CNTX $6.83
- AVG Volume (30 Days)
- PHX 50.9K
- CNTX 298.6K
- Earning Date
- PHX 11-06-2024
- CNTX 11-06-2024
- Dividend Yield
- PHX 4.68%
- CNTX N/A
- EPS Growth
- PHX N/A
- CNTX N/A
- EPS
- PHX 0.13
- CNTX N/A
- Revenue
- PHX $34,611,970.00
- CNTX N/A
- Revenue This Year
- PHX $5.46
- CNTX N/A
- Revenue Next Year
- PHX $23.19
- CNTX N/A
- P/E Ratio
- PHX $26.84
- CNTX N/A
- Revenue Growth
- PHX N/A
- CNTX N/A
- 52 Week Low
- PHX $2.95
- CNTX $0.77
- 52 Week High
- PHX $3.74
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- PHX 43.02
- CNTX 40.61
- Support Level
- PHX $3.30
- CNTX $2.14
- Resistance Level
- PHX $3.70
- CNTX $2.32
- Average True Range (ATR)
- PHX 0.13
- CNTX 0.17
- MACD
- PHX -0.03
- CNTX -0.02
- Stochastic Oscillator
- PHX 36.46
- CNTX 7.25
About PHX PHX Minerals Inc.
PHX Minerals Inc is an oil and natural gas mineral company that has employed a plan to shift the core of its business away from drilling and toward perpetual mineral and natural gas ownership. The company owns substantial mineral acreage, principally in Oklahoma, North Dakota, Texas, New Mexico, and Arkansas, but still maintains legacy interests in natural gas and oil properties that have retired operations. The revenues is derived from royalties granted from the production and sale of natural gas, oil and NGL, and the remaining portion of its revenues is derived from the production and sale of natural gas, oil and NGL on its working interests.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.